Literature DB >> 20733318

Lipid rafts, pseudotyping, and virus-like particles: relevance of a novel, configurable, and modular antigen-presenting platform.

Hans J Kueng1, Klaus G Schmetterer, Winfried F Pickl.   

Abstract

Antigen presentation by professional antigen-presenting cells (APC) is the first step towards the initiation of an adaptive immune response carried out by naïve T lymphocytes. For this purpose, antigens are presented in the form of peptide/major histocompatibility complexes (pMHC) on APC to the antigen receptor of T cells. For sustained T cell activation to occur, numerous additional molecules specifically expressed on the surface of APC have to synergize with pMHC to stimulate a given T lymphocyte. Moreover, soluble factors such as cytokines critically contribute to the specific milieu during T cell activation. APC 'talk' to T cells only when they engage in intimate physical interaction. The cell biological correlate of this APC-T cell interaction is commonly referred to as the formation of an immunological synapse. In this review we aim to provide an overview of a novel cell-free antigen-presenting platform, i.e. virus-like particles (VLP) decorated with immune receptors of choice, which was devised to overcome the molecular and cell biological complexity of the APC side of the immunological synapse. In the past we have demonstrated that immune receptor-decorated VLP are able to activate, modulate, or abrogate antigen-specific T lymphocyte responses. Thus, antigen-specific VLP represent a valuable tool which might help to explore and understand the function of antigen-specific T lymphocytes in more detail and might thus open new avenues for the modulation of pathologic T lymphocyte responses, e.g. for the treatment of allergic diseases.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20733318     DOI: 10.1159/000320224

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  7 in total

1.  Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts.

Authors:  Lisa A Lopez; Su Jung Yang; Colin M Exline; Srinivas Rengarajan; Kevin G Haworth; Paula M Cannon
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

2.  CD8+ T Cell Fate and Function Influenced by Antigen-Specific Virus-Like Nanoparticles Co-Expressing Membrane Tethered IL-2.

Authors:  Daniela Wojta-Stremayr; Alina Neunkirchner; Bharani Srinivasan; Doris Trapin; Klaus G Schmetterer; Winfried F Pickl
Journal:  PLoS One       Date:  2015-05-06       Impact factor: 3.240

3.  Exosomes in prostate cancer: putting together the pieces of a puzzle.

Authors:  Carolina Soekmadji; Pamela J Russell; Colleen C Nelson
Journal:  Cancers (Basel)       Date:  2013-11-11       Impact factor: 6.639

4.  Immune Protection of Retroviral Vectors Upon Molecular Painting with the Complement Regulatory Protein CD59.

Authors:  Susanne Heider; Sandra Kleinberger; Feliks Kochan; John A Dangerfield; Christoph Metzner
Journal:  Mol Biotechnol       Date:  2016-07       Impact factor: 2.695

Review 5.  Biomedical applications of glycosylphosphatidylinositol-anchored proteins.

Authors:  Susanne Heider; John A Dangerfield; Christoph Metzner
Journal:  J Lipid Res       Date:  2016-08-19       Impact factor: 5.922

6.  Prevention of allergy by virus-like nanoparticles (VNP) delivering shielded versions of major allergens in a humanized murine allergy model.

Authors:  Bernhard Kratzer; Cordula Köhler; Sandra Hofer; Ursula Smole; Doris Trapin; Jagoba Iturri; Dietmar Pum; Philip Kienzl; Adelheid Elbe-Bürger; Pia Gattinger; Irene Mittermann; Birgit Linhart; Gabriele Gadermaier; Beatrice Jahn-Schmid; Alina Neunkirchner; Rudolf Valenta; Winfried F Pickl
Journal:  Allergy       Date:  2018-11-05       Impact factor: 13.146

Review 7.  All the small things: How virus-like particles and liposomes modulate allergic immune responses.

Authors:  Bernhard Kratzer; Sandra Hofer; Maja Zabel; Winfried F Pickl
Journal:  Eur J Immunol       Date:  2019-12-15       Impact factor: 5.532

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.